Pharma companies want to change drug price negotiation rules. Should the government oblige?

Cheaper drugs or new innovative treatments?

That's what pharmaceutical companies — including some with Boston ties — say they'll have to choose between if the federal government doesn't change its rules about drug price negotiations.

Is that true, or are pharma companies just trying to make more money off of drugs some believe are already too expensive?

Boston Globe reporter Rob Weisman joins the show to discuss.